Narisse E Kendrick, MD
Obstetrics/Gynecology · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 25
- 5 carriers
- Office
- 1
Offices
1 location
Looking this up.
Hospitals listed: Good Samaritan Hospital. That is not proof they admit you there this week.
Plans that list them
25 plans · 5 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Kendrick’s office at (408) 356-8681 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
25 of 25 plans
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence G79000 · Current
Licensed to practise in California · since 1994 · expires 2028-05-31 · Yale University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Good Samaritan HospitalSan Jose, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.337, Oct 2024 – Sep 2025
See every measure and the patient survey for Good Samaritan Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.337 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.75 (0 to 1.67) · 1,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.84 (0.54 to 1.14) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 143.59 (98.7 to 188.49) · 98 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.7 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.3 · 573 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 820 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.5 · 482 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 3,711 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.12 (0 to 0.3) · 8,866 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.38) · 9,051 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.65 (0.74 to 4.56) · 1,929 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.8 (0.21 to 3.39) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.88 to 3.78) · 1,836 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.73 (0 to 13.46) · 669 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.58 (3.96 to 11.19) · 654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.59 (0.13 to 3.04) · 496 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 0.87) · 7,373 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 152 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.08 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.542 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.484 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.565 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 327 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 24.2 · 703 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 61.1 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 36.3 · 665 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.4 · 856 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19 · 978 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.2 · 135 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.8 (10.1 to 18.6) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 531 cases | No different | Jan 2024 – Dec 2024 |
What patients said (704 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 38% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$12,006
Medicare paid this office $12,006 for 78 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 47 | $2,696 | $57 |
| Return visit (30+ min) | 15 | $2,276 | $114 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 47 | $2,247 | $48 |
| Short return visit (20+ min) | 11 | $1,040 | $87 |
| Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | 49 | $867 | $18 |
Who their Medicare patients are
78 Original Medicare patients in 2024. Average age 70 · Women 100% · Health risk score 0.61. At or below the middle of the specialty; the typical obstetrics & gynecology clinician is at 0.88.
Conditions among them: High blood pressure 54% · Diabetes 21% · Coronary heart disease 15%.
The office billed $31,329, Medicare allowed $14,015 and paid $12,006; for 210 services of 16 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 78 | 210 | 70 | 0.61 | $31,329 | $12,006 |
| 2023 | 120 | 357 | 70 | 0.63 | $47,376 | $17,474 |
| 2022 | 96 | 277 | 71 | 0.67 | $39,893 | $14,344 |
| 2021 | 88 | 253 | 69 | 0.55 | $35,323 | $13,324 |
| 2020 | 84 | 228 | 69 | 0.75 | $27,698 | $9,748 |
| 2019 | 88 | 266 | 69 | 0.61 | $44,618 | $13,830 |
| 2018 | 79 | 234 | 70 | 0.65 | $39,573 | $12,875 |
| 2017 | 72 | 180 | 69 | 0.76 | $32,388 | $9,735 |
| 2016 | 65 | 163 | 69 | 0.62 | $31,639 | $10,821 |
| 2015 | 58 | 133 | 69 | 0.70 | $21,088 | $7,326 |
| 2014 | 26 | 61 | 68 | 0.99 | $25,442 | $3,073 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 5 services
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 88 | $4,917 | $56 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 86 | $4,110 | $48 |
| Short return visit (20+ min) | 21 | $2,174 | $78 |
| Return visit (30+ min) | 14 | $1,835 | $102 |
| Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | 96 | $1,698 | $18 |
2022: 6 services
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 65 | $3,574 | $55 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 66 | $3,146 | $48 |
| Return visit (30+ min) | 15 | $2,509 | $119 |
| Short return visit (20+ min) | 15 | $1,417 | $71 |
| Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | 70 | $1,246 | $18 |
| Urinalysis, manual test | 12 | $48 | $3 |
2021: 5 services
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 62 | $3,457 | $56 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 62 | $3,006 | $48 |
| Return visit (30+ min) | 12 | $1,856 | $124 |
| Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | 68 | $1,227 | $18 |
| Short return visit (20+ min) | 12 | $1,070 | $89 |
2020: 4 services
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 60 | $3,286 | $55 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 59 | $2,848 | $48 |
| Return visit (30+ min) | 17 | $1,388 | $77 |
| Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | 59 | $1,060 | $18 |
2019: 4 services
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 68 | $3,666 | $54 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 69 | $3,215 | $47 |
| Return visit (30+ min) | 19 | $2,232 | $93 |
| Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | 67 | $1,185 | $18 |
2018: 4 services
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 59 | $3,165 | $54 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 57 | $2,520 | $44 |
| Short return visit (20+ min) | 17 | $1,269 | $58 |
| Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | 56 | $1,078 | $19 |
2017: 4 services
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 41 | $2,148 | $52 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 41 | $1,827 | $45 |
| Short return visit (20+ min) | 19 | $1,451 | $50 |
| Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | 39 | $834 | $21 |
2016: 4 services
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 44 | $1,954 | $44 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 43 | $1,938 | $45 |
| Short return visit (20+ min) | 26 | $1,480 | $55 |
| Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | 19 | $404 | $21 |
2015: 3 services
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 35 | $1,572 | $45 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 34 | $1,533 | $45 |
| Stool analysis for blood to screen for colon tumors | 26 | $113 | $4 |
2014: 2 services
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 22 | $992 | $45 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 21 | $943 | $45 |
Drugs they prescribed that Part D paid
$32,029
Pharmacies billed $32,029 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 432) in 2024. At or below the middle of the specialty; the typical obstetrics & gynecology clinician is at 0%.
364 generic and 56 brand-name prescriptions · $32,029 in drug cost · 35 antibiotic prescriptions to 14 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Estring | 12 | $6,276 | $523 |
| Estradiol | 46 | $5,231 | $114 |
| Progesterone | 66 | $2,369 | $36 |
| Estradiol (Twice Weekly) | 18 | $1,811 | $101 |
| Armour Thyroid | 11 | $1,048 | $95 |
See all 13 drugs
| Estring | 12 | $6,276 | $523 |
| Estradiol | 46 | $5,231 | $114 |
| Progesterone | 66 | $2,369 | $36 |
| Estradiol (Twice Weekly) | 18 | $1,811 | $101 |
| Armour Thyroid | 11 | $1,048 | $95 |
| Valacyclovir | 14 | $584 | $42 |
| Clobetasol Propionate | 12 | $525 | $44 |
| Nitrofurantoin Mono-Macro | 16 | $328 | $20 |
| Zolpidem | 35 | $119 | $3 |
| Fluconazole | 11 | $83 | $8 |
| Diazepam | 11 | $32 | $3 |
| Lorazepam | 11 | $27 | $2 |
| Alprazolam | 14 | $8 | $1 |
Year by year
| 2024 | 432 | 89 | 0% (0) | 13% | $32,029 |
| 2023 | 346 | 73 | 0% (0) | None | $31,258 |
| 2022 | 236 | 51 | None | None | $21,481 |
| 2021 | 260 | 55 | None | None | $33,690 |
| 2020 | 212 | 50 | None | 21% | $29,455 |
| 2019 | 206 | 45 | None | 22% | $28,444 |
| 2018 | 173 | 39 | None | 20% | $14,535 |
| 2017 | 174 | 34 | None | 9% | $11,791 |
| 2016 | 112 | 24 | None | 26% | $9,219 |
| 2015 | 97 | 27 | None | 36% | $8,953 |
| 2014 | 49 | 18 | 0% (0) | 39% | $6,169 |
| 2013 | 57 | 15 | None | None | $4,679 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 9 drugs
| Premarin | 14 | $7,299 | $521 |
| Estradiol | 33 | $3,871 | $117 |
| Progesterone | 50 | $3,130 | $63 |
| Estradiol (Twice Weekly) | 18 | $1,925 | $107 |
| Valacyclovir | 19 | $911 | $48 |
| Clotrimazole-Betamethasone | 19 | $477 | $25 |
| Fluconazole | 22 | $465 | $21 |
| Zolpidem | 25 | $166 | $7 |
| Alprazolam | 16 | $71 | $4 |
2022: 9 drugs
| Estradiol (Twice Weekly) | 15 | $2,859 | $191 |
| Estradiol | 19 | $2,051 | $108 |
| Progesterone | 21 | $1,875 | $89 |
| Valacyclovir | 14 | $986 | $70 |
| Clotrimazole-Betamethasone | 12 | $524 | $44 |
| Nitrofurantoin Mono-Macro | 13 | $502 | $39 |
| Fluconazole | 19 | $443 | $23 |
| Zolpidem | 20 | $279 | $14 |
| Spironolactone | 11 | $277 | $25 |
2021: 10 drugs
| Myrbetriq | 16 | $12,163 | $760 |
| Estradiol (Twice Weekly) | 14 | $2,231 | $159 |
| Progesterone | 22 | $1,863 | $85 |
| Estradiol | 22 | $1,672 | $76 |
| Estradiol (Once Weekly) | 14 | $1,311 | $94 |
| Valacyclovir | 11 | $1,014 | $92 |
| Clotrimazole-Betamethasone | 15 | $408 | $27 |
| Spironolactone | 11 | $219 | $20 |
| Temazepam | 17 | $109 | $6 |
| Zolpidem | 17 | $53 | $3 |
2020: 6 drugs
| Myrbetriq | 21 | $17,352 | $826 |
| Estradiol | 15 | $1,578 | $105 |
| Progesterone | 18 | $1,331 | $74 |
| Temazepam | 12 | $184 | $15 |
| Zolpidem | 24 | $104 | $4 |
| Alendronate | 12 | $50 | $4 |
2019: 7 drugs
| Myrbetriq | 14 | $15,462 | $1,104 |
| Estradiol | 40 | $3,293 | $82 |
| Progesterone | 14 | $1,203 | $86 |
| Zolpidem | 13 | $165 | $13 |
| Temazepam | 17 | $131 | $8 |
| Diazepam | 12 | $59 | $5 |
| Alendronate | 11 | $58 | $5 |
2018: 5 drugs
| Estradiol | 33 | $2,632 | $80 |
| Jinteli | 12 | $1,261 | $105 |
| Zolpidem | 16 | $115 | $7 |
| Diazepam | 11 | $57 | $5 |
| Alendronate | 12 | $38 | $3 |
2017: 7 drugs
| Estradiol | 23 | $551 | $24 |
| Clotrimazole-Betamethasone | 12 | $504 | $42 |
| Progesterone | 11 | $489 | $44 |
| Valacyclovir | 14 | $270 | $19 |
| Alendronate | 14 | $75 | $5 |
| Zolpidem | 13 | $36 | $3 |
| Glipizide | 11 | $18 | $2 |
2016: 3 drugs
| Progesterone | 16 | $681 | $43 |
| Valacyclovir | 11 | $233 | $21 |
| Estropipate | 12 | $140 | $12 |
2015: 2 drugs
| Progesterone | 16 | $778 | $49 |
| Alendronate | 11 | $55 | $5 |
2014: 1 drug
| Fluoxetine | 12 | $66 | $5 |
2013: 1 drug
| Estradiol | 16 | $349 | $22 |
Money from drug and device companies
$507 in 2025
| 2025 | 5 | 16 | None | $507 |
| 2024 | 13 | 39 | None | $785 |
| 2023 | 10 | 43 | None | $1,020 |
| 2022 | 11 | 42 | None | $612 |
| 2021 | 8 | 42 | None | $558 |
| 2020 | 6 | 16 | None | $341 |
| 2019 | 9 | 23 | None | $334 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Millicent US | Femlyv | $218 | 3 payments
|
| Mayne Pharma Commercial | None | $115 | 7 payments
|
| Exact Sciences | Cologuard Collection Kit | $92 | 4 payments
|
| Intuitive Surgical | Da Vinci Surgical System | $67 | 1 payment
|
| CooperSurgical | Paragard T 380a | $16 | 1 payment
|
See all 16 published payments
| Mayne Pharma Commercial | Meals · 2025-12-03 | None | $25 |
| Intuitive Surgical | Meals · 2025-11-11 | Da Vinci Surgical System | $67 |
| Exact Sciences | Meals · 2025-11-05 | Cologuard Collection Kit | $27 |
| Millicent US | Meals · 2025-09-10 | Femlyv | $20 |
| Exact Sciences | Meals · 2025-07-30 | Cologuard Collection Kit | $26 |
| Exact Sciences | Meals · 2025-07-02 | Cologuard Collection Kit | $15 |
| Mayne Pharma Commercial | Meals · 2025-07-02 | None | $9 |
| Mayne Pharma Commercial | Meals · 2025-06-11 | None | $9 |
| Mayne Pharma Commercial | Meals · 2025-05-28 | None | $26 |
| Exact Sciences | Meals · 2025-04-16 | Cologuard Collection Kit | $24 |
| Mayne Pharma Commercial | Meals · 2025-04-09 | None | $19 |
| CooperSurgical | Meals · 2025-03-05 | Paragard T 380a | $16 |
| Mayne Pharma Commercial | Meals · 2025-02-20 | None | $23 |
| Millicent US | Meals · 2025-02-06 | Femring | $18 |
| Millicent US | Education · 2025-02-05 | None | $180 |
| Mayne Pharma Commercial | Meals · 2025-01-28 | None | $4 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $785
| Mayne Pharma Commercial | None | $157 | 13 payments
|
| Terumo Medical | Hydropearl | $143 | 2 payments
|
| Exact Sciences | Cologuard Collection Kit | $137 | 6 payments
|
| Pfizer | Nurtec Odt | $78 | 4 payments
|
| Exeltis USA | Tyblume | $62 | 3 payments
|
| Abbvie | Ubrelvy | $53 | 3 payments
|
| Sumitomo Pharma America | Myfembree | $33 | 2 payments
|
| Agile Therapeutics | Twirla | $24 | 1 payment
|
| Minerva Surgical | None | $21 | 1 payment
|
| Millicent US | Femring | $21 | 1 payment
|
| Bausch Health US | Aplenzin | $21 | 1 payment
|
| Meditrina | None | $19 | 1 payment
|
| Evofem Biosciences | None | $17 | 1 payment
|
2023: $1,020
| Mayne Pharma Commercial | Nextstellis | $306 | 12 payments
|
| Exact Sciences | Cologuard Collection Kit | $258 | 9 payments
|
| Abbvie | Qulipta | $174 | 9 payments
|
| Bausch Health US | Aplenzin | $79 | 4 payments
|
| Organon | Nexplanon | $54 | 2 payments
|
| Pfizer | Myfembree | $48 | 2 payments
|
| Evofem Biosciences | Phexxi | $34 | 2 payments
|
| Acella Pharmaceuticals | NP Thyroid 60 | $25 | 1 payment
|
| Sumitomo Pharma America | Myfembree | $21 | 1 payment
|
| Agile Therapeutics | Twirla | $20 | 1 payment
|
2022: $612
| Abbvie | Lo Loestrin Fe | $156 | 9 payments
|
| TherapeuticsMD | Annovera | $140 | 17 payments
|
| Biohaven Pharmaceutical Holding Company | Nurtec Odt | $74 | 4 payments
|
| Bausch Health US | Aplenzin | $65 | 3 payments
|
| Mayne Pharma | None | $57 | 3 payments
|
| Agile Therapeutics | Twirla | $24 | 1 payment
|
| Myovant Sciences | Myfembree | $22 | 1 payment
|
| Allergan | None | $22 | 1 payment
|
| DySIS Medical | Dysis Ultra | $19 | 1 payment
|
| Evofem Biosciences | Phexxi | $18 | 1 payment
|
| Avion Pharmaceuticals | Balcoltra | $15 | 1 payment
|
2021: $558
| AbbVie | Liletta | $309 | 20 payments
|
| TherapeuticsMD | Annovera | $116 | 15 payments
|
| Bausch Health US | Aplenzin | $39 | 2 payments
|
| Becton Dickinson and | None | $23 | 1 payment
|
| Mylan Pharmaceuticals | Xulane | $20 | 1 payment
|
| Roche Diagnostics | Cintec Plus Cytology | $20 | 1 payment
|
| Myovant Sciences | Myfembree | $17 | 1 payment
|
| Organon | Nexplanon | $13 | 1 payment
|
2020: $341
| AbbVie | Orilissa | $197 | 9 payments
|
| TherapeuticsMD | Imvexxy | $51 | 3 payments
|
| Merck Sharp & Dohme | Nexplanon | $27 | 1 payment
|
| Lupin | Solosec | $23 | 1 payment
|
| Allergan | Ubrelvy | $21 | 1 payment
|
| Roche Diagnostics | Td Benchmark Platforms | $20 | 1 payment
|
2019: $334
| AbbVie | Orilissa | $109 | 11 payments
|
| Allergan | Lo Loestrin Fe | $53 | 3 payments
|
| Roche Diagnostics | Rs Harmony Test Related Products | $42 | 2 payments
|
| Bayer HealthCare Pharmaceuticals | Kyleena | $32 | 2 payments
|
| Boston Scientific | Symphion | $24 | 1 payment
|
| Hologic | Aptima Hpv | $20 | 1 payment
|
| AMAG Pharmaceuticals | Intrarosa | $19 | 1 payment
|
| Lupin | Solosec | $18 | 1 payment
|
| TherapeuticsMD | Annovera | $17 | 1 payment
|
Professional record
- NPI
- 1205893286
- Licence
- CA G79000California G79000: Current · expires 2028-05-31
- Trained
- Yale University School of Medicine, 1991
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 174400000X (174400000X)
- Mailing address
- 5570 Sanchez Dr Ste 110, San Jose, CA, 95123
- NPI first listed
- 2006-04-26
- NPI last updated
- 2022-07-21
This is when the NPI record was last certified, not a medical board exam.